News & Updates
Showing Oncology articles
Showing
Dalpiciclib a 1L option for HR-positive, HER2-negative advanced breast cancer regardless of menopausal status
Adding dalpiciclib to an aromatase inhibitor (AI) significantly improves progression-free survival (PFS) vs an AI alone in first-line (1L) treatment of hormone receptor (HR)–positive, HER2-negative advanced breast cancer regardless of patients’ menopausal status, a phase III trial in 42 hospitals in China has shown.
Breast cancer deaths highest within 5 years from diagnosis, decrease afterwards
The risk of mortality for women with early invasive breast cancer is highest during the 5 years after diagnosis, according to a study. Deaths from breast cancer will continue beyond this point, but such risk tends to decrease during each subsequent 5-year period.
Sacituzumab govitecan proven safe, effective in metastatic breast cancer
Treatment with sacituzumab govitecan (SG) demonstrates clinically meaningful overall survival (OS) over single-agent chemotherapy in patients with pretreated, endocrine-resistant, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), as confirmed by the final OS analysis from the TROPiCS-02 study, presented at ASCO 2023.